{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:39:28Z","timestamp":1787812768911,"version":"build-2784847793"},"reference-count":25,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2023]]},"DOI":"10.1620\/tjem.2023.j006","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T22:10:27Z","timestamp":1674684627000},"page":"13-20","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study"],"prefix":"10.1620","volume":"260","author":[{"given":"Wei","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wuhan First Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O.B. &amp; Minko, T. (2018)  Metastatic and triple-negative breast cancer: challenges and treatment options.  <i>Drug Deliv. Transl. Res.<\/i>, 8, 1483-1507.","DOI":"10.1007\/s13346-018-0551-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Borri, F. &amp; Granaglia, A. (2021)  Pathology of triple negative breast cancer. <i>Semin.  Cancer Biol.<\/i>, 72, 136-145.","DOI":"10.1016\/j.semcancer.2020.06.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Chi, Y., Wang, F., Zhang, Y., Shan, Z., Tao, W., Lian, Y., Xin, D., Fan, Q. &amp; Sun, Y. (2022)  Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma.  <i>J. Cell. Mol. Med.<\/i>, 26, 1905-1917.","DOI":"10.1111\/jcmm.17209"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Derakhshan, F. &amp; Reis-Filho, J.S. (2022)  Pathogenesis of triple-negative breast cancer.  <i>Annu. Rev. Pathol.<\/i>, 17, 181-204.","DOI":"10.1146\/annurev-pathol-042420-093238"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Enzenbach, C., Wicklein, B., Wirkner, K. &amp; Loeffler, M. (2019)  Evaluating selection bias in a population-based cohort study with low baseline participation: the LIFE-Adult-Study.  <i>BMC Med. Res. Methodol.<\/i>, 19, 135.","DOI":"10.1186\/s12874-019-0779-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Feng, J. &amp; Qin, S. (2018)  The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model.  <i>Onco Targets Ther.<\/i>, 11, 3047-3057.","DOI":"10.2147\/OTT.S159935"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hu, N., Zhu, A., Si, Y., Yue, J., Wang, X., Wang, J., Ma, F., Xu, B. &amp; Yuan, P. (2020)  A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer.  <i>Front. Oncol.<\/i>, 10, 565384.","DOI":"10.3389\/fonc.2020.565384"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hu, X., Zhang, J., Xu, B., Jiang, Z., Ragaz, J., Tong, Z., Zhang, Q., Wang, X., Feng, J., Pang, D., Fan, M., Li, J., Wang, B., Wang, Z., Zhang, Q., et al.  (2014)  Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.  <i>Int. J. Cancer<\/i>, 135, 1961-1969.","DOI":"10.1002\/ijc.28829"},{"key":"9","unstructured":"Huang, X. &amp; Yin, Y.M. (2018)  Updates of Chinese Society of Clinical Oncology (CSCO)  guideline for breast cancer in 2018.  <i>Zhonghua Yi Xue Za Zhi<\/i>, 98, 1213-1217."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Hwang, S.Y., Park, S. &amp; Kwon, Y. (2019)  Recent therapeutic trends and promising targets in triple negative breast cancer.  <i>Pharmacol. Ther.<\/i>, 199, 30-57.","DOI":"10.1016\/j.pharmthera.2019.02.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Li, Q., Liu, J., Jiang, Z. &amp; Liu, Q. (2020)  CSCO breast cancer guideline: precise, economical and oriental.  <i>Sci. China Life Sci.<\/i>, 63, 1410-1412.","DOI":"10.1007\/s11427-020-1701-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Li, Y.H., Zhou, Y., Wang, Y.W., Tong, L., Jiang, R.X., Xiao, L., Zhang, G.J., Xing, S.S., Qian, F., Feng, J.Q., Zhao, Y.L., Wang, J.G. &amp; Wang, X.H. (2018)  Comparison of apatinib and capecitabine (Xeloda)  with capecitabine (Xeloda)  in advanced triple-negative breast cancer as third-line therapy: a retrospective study.  <i>Medicine <\/i>(<i>Baltimore<\/i>), 97, e12222.","DOI":"10.1097\/MD.0000000000012222"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., Lau, W.Y., Jiang, Z. &amp; Song, E. (2020)  Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.  <i>J. Immunother. Cancer<\/i>, 8, e000696.","DOI":"10.1136\/jitc-2020-000696"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Liu, Z., Shan, J., Yu, Q., Wang, X., Song, X., Wang, F., Li, C., Yu, Z. &amp; Yu, J. (2021)  Real-world data on apatinib efficacy - results of a retrospective study in metastatic breast cancer patients pretreated with multiline treatment.  <i>Front. Oncol.<\/i>, 11, 643654.","DOI":"10.3389\/fonc.2021.643654"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Manthri, S., Sharma, P., Mejbel, H.A., Singal, S. &amp; Jaishankar, D. (2020)  Third line eribulin for triple-negative metastatic breast ductal carcinoma resulting in extended progression-free survival of 57 months.  <i>Cureus<\/i>, 12, e6980.","DOI":"10.7759\/cureus.6980"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Schilling, J., Busch, S., Heinrich, G., Heinig, K., Martin Kurbacher, C., Klare, P. &amp; Pollinger, B. (2019)  Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN).  <i>Curr. Med. Res. Opin.<\/i>, 35, 1405-1414.","DOI":"10.1080\/03007995.2019.1595551"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., Dieras, V., Hegg, R., Im, S.A., Shaw Wright, G., Henschel, V., Molinero, L., Chui, S.Y., Funke, R., Husain, A., et al.  (2018)  Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.  <i>N. Engl. J. Med.<\/i>, 379, 2108-2121.","DOI":"10.1056\/NEJMoa1809615"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Scott, L.J. (2018)  Apatinib: a review in advanced gastric cancer and other advanced cancers.  <i>Drugs<\/i>, 78, 747-758.","DOI":"10.1007\/s40265-018-0903-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Valerio, M.R., Arrivas Bajardi, E., Arcara, C.C., Borsellino, N., Lo Mauro, M., Cipolla, C., Santarpia, M., Firenze, A., Motta, G., Vigneri, P. &amp; Gebbia, V. (2021)  Eribulin mesylate for the treatment of metastatic hormone-refractory and triple-negative breast cancer: a multi-institutional real-world report on efficacy and safety.  <i>Am. J. Clin. Oncol.<\/i>, 44, 105-108.","DOI":"10.1097\/COC.0000000000000790"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Wang, Q., Gao, J., Di, W. &amp; Wu, X. (2020)  Anti-angiogenesis therapy overcomes the innate resistance to PD-1\/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.  <i>Cancer Immunol. Immunother.<\/i>, 69, 1781-1799.","DOI":"10.1007\/s00262-020-02576-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Won, K.A. &amp; Spruck, C. (2020)  Triplenegative breast cancer therapy: current and future perspectives (review).  <i>Int. J. Oncol.<\/i>, 57, 1245-1261.","DOI":"10.3892\/ijo.2020.5135"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Xu, Z., Hu, C., Chen, S., Zhang, C., Yu, J., Wang, X., Lv, H. &amp; Cheng, X. (2019)  Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil.  <i>Cancer Manag. Res.<\/i>, 11, 4905-4915.","DOI":"10.2147\/CMAR.S196372"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Yuan, P., Di, L., Zhang, X., Yan, M., Wan, D., Li, L., Zhang, Y., Cai, J., Dai, H., Zhu, Q., Hong, R. &amp; Xu, B. (2015)  Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study.  <i>Medicine <\/i>(<i>Baltimore<\/i>), 94, e774.","DOI":"10.1097\/MD.0000000000000774"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Yang, W., Ma, F., Ma, Q., Zhang, B., Zhang, Y., Liu, Y., Liu, H. &amp; Hua, Y. (2020)  Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis.  <i>Drug Deliv.<\/i>, 27, 691-702.","DOI":"10.1080\/10717544.2020.1754528"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Zhao, D., Hou, H. &amp; Zhang, X. (2018)  Progress in the treatment of solid tumors with apatinib: a systematic review.  <i>Onco Targets Ther.<\/i>, 11, 4137-4147.","DOI":"10.2147\/OTT.S172305"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/1\/260_2023.J006\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T04:06:36Z","timestamp":1683950796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/260\/1\/260_2023.J006\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2023.j006","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"2023.J006"}}